Search
Paclitaxel Treatment Options
A collection of 2017 research studies where Paclitaxel is the interventional treatment. These studies are located in the United States. Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.
925 - 936 of 2017
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Studying an Investigational Virus Vaccine
Recruiting
The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.
Conditions:
Healthy
Interested in vaccine studies
All Conditions
Preventative Trials
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Trial
Evaluating an Investigational Treatment for Hidradenitis Suppurativa
Recruiting
The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.
Conditions:
All Conditions
Hidradenitis suppurativa (Skin disorder)
Dermatology
Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cysts
Completed
The purpose of this study is to track outcomes and complications of patients at IUMC referred by physicians for EUS-guided pancreatic cyst ablation. This information is essential in order to disseminate future published information to physicians about this technique. A database will be created to track these patients undergoing an already scheduled/planned procedure. Phone calls at selected intervals will be made following the procedure to track any complications that occur
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/06/2022
Locations: Indiana University Hospital, Indianapolis, Indiana
Conditions: Pancreatic Cyst, Pancreatic Intraductal Papillary-Mucinous Neoplasm, Cystadenoma, Mucinous, Papillary Mucinous Cystadenoma, Borderline Malignancy
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Terminated
The purpose of the Study is to select a dose and assess the safety and tolerability of INCB057643 as a monotherapy (Part 1 and Part 2) and in combination with standard-of-care (SOC) agents (Part 3 and Part 4) for subjects with advanced malignancies.
Part 1 will determine the maximum tolerated dose of INCB057643 and/or a tolerated dose that demonstrates sufficient pharmacologic activity. Part 2 will further evaluate the safety, preliminary efficacy, PK, and PD of the dose(s) selected in Part 1 i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2022
Locations: University of Alabama, Birmingham, Alabama +17 locations
Conditions: Solid Tumors
A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer
Completed
In this Phase I/II clinical trial, the investigators seek to pilot the addition of Hydroxychloroquine (HCQ) to a commonly-used front-line therapy of pancreatic cancer, gemcitabine/nab-paclitaxel. The investigators plan a run-in to define tolerable doses, and will explore doses of 800 and 1200 mg/day in successive cohorts of 6 patients. The investigators will assess toxicity continuously, and determine the dose for the Phase II trial based on standard toxicity criteria.
The correlative endpoints... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/29/2022
Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Advanced Adenocarcinoma, Metastatic Adenocarcinoma
Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
Terminated
The purpose of this study is to determine the safety and tolerability of rebastinib when combined with antitubulin therapy with paclitaxel or eribulin in patients with advanced breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/23/2022
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Breast Cancer, Breast Adenocarcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Recurrent Breast Carcinoma, Stage IV Breast Cancer
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Completed
The purpose of the study is to estimate the response rate and compare overall survival of patients taking BMS-936558 to those taking study physician's choice of either Dacarbazine or Carboplatin and Paclitaxel
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/23/2022
Locations: Mayo Clinic, Phoenix, Arizona +94 locations
Conditions: Unresectable or Metastatic Melanoma
A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]
Completed
This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment with carboplatin + nab-paclitaxel in chemotherapy-naive participants with Stage IV squamous NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2022
Locations: Ironwood Cancer & Research Centers, Chandler, Arizona +241 locations
Conditions: Squamous Non-Small Cell Lung Cancer
An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease
Withdrawn
The purpose of this study is to determine if nivolumab added to the standard of care therapy (SOC) given after surgery is more effective than SOC alone in prolonging disease free survival in NSCLC participants with minimal residual disease detected after surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/09/2022
Locations: Local Institution, Jacksonville, Florida +12 locations
Conditions: Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, Circulating Tumor DNA
A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer
Withdrawn
Feasibility and Safety study of autologous dendritic cell immunotherapy (AGS-003-LNG) in patients with resectable non-small cell lung cancer.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
03/03/2022
Locations: Cancer Research Network of Nebraska / Oncology Associates, Omaha, Nebraska
Conditions: Non-small Cell Lung Cancer (NSCLC)
Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma
Terminated
In this multi-institution phase I/II trial, the investigators have chosen paclitaxel and carboplatin using a schedule and doses identical to those used in the CROSS trial. Following a run-in with nivolumab alone at 240 mg IVPB every 2 weeks for 2 doses, nivolumab at 240 mg every 2 weeks will be added to paclitaxel and carboplatin, which will be dosed according to the standard of care established by the CROSS trial: paclitaxel 50 mg/m2 weekly for 6 weeks and carboplatin AUC 2 weekly for 6 weeks.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/02/2022
Locations: University of Califonia, San Diego, La Jolla, California +4 locations
Conditions: Esophageal Squamous Cell Carcinoma
Trial of NanoPac Focal Therapy for Prostate Cancer
Terminated
This study evaluates the use of NanoPac injected directly into the prostate lesion in men with prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/02/2022
Locations: Moffitt Cancer Center, Tampa, Florida +3 locations
Conditions: Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Adenocarcinoma, Prostatic Neoplasm, Urogenital Neoplasms, Genital Neoplasms, Male, Localized Cancer
A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors
Completed
The purpose of this study is to assess the effect of multiple-dose administration of rifampin on the single dose PK of pevonedistat in adult participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2022
Locations: Emory University, Atlanta, Georgia +3 locations
Conditions: Advanced Solid Neoplasm
Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer
Completed
The purpose of this research study is to compare the effectiveness and safety of FKB238 against Avastin® in men and women with advanced/recurrent non squamous non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2022
Locations: Research Site 7814 - Compassionate Care Research Group, Fountain Valley, California +146 locations
Conditions: Carcinoma, Non-Small-Cell Lung
925 - 936 of 2017